Keyphrases
5α-reductase Inhibitors
10%
Age-related Conditions
10%
Aging Effect
10%
Aging Men
10%
Alpha-blockers
10%
Autonomic Nervous System
10%
Benign Prostatic Hyperplasia
100%
Common Disease
10%
Comorbid Factors
10%
Comorbidity
10%
Concomitant Medications
10%
Counseling
20%
Current Guidelines
10%
Cyclic GMP
10%
Ejaculatory Dysfunction
10%
Endothelin-1 (ET-1)
10%
Epidemiological Study
10%
Erectile Dysfunction
10%
Lifestyle Factors
10%
Lifestyle Intervention
10%
Loss of Libido
10%
Lower Urinary Tract Symptoms
90%
Male Sexual Dysfunction
10%
Medical Therapy
10%
Medical Treatment
10%
Metabolic Syndrome
10%
Negative Impact
10%
Nitric Oxide
10%
Older Men
10%
Overactivity
10%
Pathophysiological Mechanisms
10%
Pelvic Organs
10%
Pharmacotherapy
10%
Physical Activity
10%
Primary Care Physicians
10%
Quality of Life
10%
Randomized Controlled Trial
10%
Rho Kinase
10%
Risk Factors
10%
Sexual Adverse Effects
20%
Sexual Adverse Events
100%
Sexual Behavior
100%
Sexual Dysfunction
70%
Sexual Satisfaction
10%
Treatment Impact
100%
Treatment Options
10%
Urologists
10%
Validated Questionnaire
10%
Weight Loss
10%
Medicine and Dentistry
Adverse Event
100%
Alpha Adrenergic Receptor Blocking Agent
10%
Atherosclerosis
10%
Autonomic Nervous System
10%
Combination Therapy
20%
Comorbidity
20%
Counseling
10%
Cyclic GMP
10%
Disease
10%
Drug Therapy
20%
Ejaculatory Disorder
10%
Endothelin 1
10%
Erectile Dysfunction
10%
Libido Disorder
10%
Lifestyle Intervention
10%
Lower Urinary Tract Symptom
90%
Metabolic Syndrome
10%
Nitric Oxide
10%
Pelvis
10%
Physical Activity
10%
Primary Health Care
10%
Prostate Hypertrophy
100%
Quality of Life
10%
Randomized Controlled Trial
10%
Rho Kinase
10%
Steroid 5alpha Reductase Inhibitor
10%
Urologist
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Alpha Adrenergic Receptor Blocking Agent
10%
Atherosclerosis
10%
Combination Therapy
20%
Comorbidity
20%
Cyclic GMP
10%
Disease
20%
Endothelin 1
10%
Erectile Dysfunction
10%
Libido Disorder
10%
Lower Urinary Tract Symptom
90%
Metabolic Syndrome X
10%
Nitric Oxide
10%
Pharmacotherapy
10%
Prostate Hypertrophy
100%
Randomized Controlled Trial
10%
Rho Kinase
10%
Steroid 5alpha Reductase Inhibitor
10%